Royal NorthShore Hospital
Saint Leonards, New South Wales 2065
7 studies enrolling now · 34 studies all time
What they study most
Astrocytoma, Grade IV, Astrocytoma, IDH-Mutant, Grade 2, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Autosomal Dominant Hypocalcemia, Autosomal Dominant Hypocalcemia (ADH), Chronic Lymphocytic Leukemia (CLL), Coronary Artery Disease, Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Endometrial Cancer
Studies at this site
- Brentuximab Vedotin in Early Stage Hodgkin Lymphoma — Recruiting now
- SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) — Recruiting now
- Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease — Recruiting now
- A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies — Recruiting now
- A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment — Recruiting now
- Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD) — Recruiting now
- Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients — Running, not enrolling
- Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes — Running, not enrolling
- Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1 — Running, not enrolling
- Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese — Completed
- Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma — Running, not enrolling
- Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D) — Running, not enrolling
- ADH1 and ADH2 Disease Monitoring Study (DMS) — Running, not enrolling
- Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses — Completed
- A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis — Completed
- Olorofim Aspergillus Infection Study — Running, not enrolling
- CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) — Running, not enrolling
- A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia — Running, not enrolling
- An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005) — Completed
- Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis — Running, not enrolling
- A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies. — Completed
- An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP) — Completed
- Distal Evaluation of Functional Performance with Intravascular Sensors to Assess the Narrowing Effect: Guided Physiologic Stenting — Enrolling by invitation
- Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM — Running, not enrolling
- Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial — Completed
- Phase 3 Study to Treat Patients With Soft Tissue Sarcomas — Completed
- An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva. — Completed
- A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) — Completed
- A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) — Stopped early
- Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients — Completed
- A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer — Status unconfirmed
- Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET — Completed
- TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy — Stopped early
- Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer — Completed